Saxenda in Australia 2026: Cost, How It Compares to Wegovy & Mounjaro
Key Takeaways
Saxenda was Australia's first GLP-1 weight loss injection — but in 2026 it faces much stronger competition. Current Saxenda costs, how daily liraglutide compares to weekly semaglutide and tirzepatide, and who it still suits.
Before Ozempic dominated headlines, before Wegovy and Mounjaro arrived, there was Saxenda — the first GLP-1 medication TGA-approved for weight management in Australia. It's still prescribed in 2026, but the landscape around it has changed completely. Here's an honest look at where Saxenda fits now.
What is Saxenda?
Saxenda is liraglutide, a GLP-1 receptor agonist — the same drug class as semaglutide (Ozempic, Wegovy). It suppresses appetite, slows stomach emptying and helps regulate blood sugar. The defining practical difference: Saxenda is a daily injection, while Wegovy, Ozempic and Mounjaro are weekly.
How much does Saxenda cost in Australia?
Saxenda is not PBS-subsidised, so you pay the private price — typically $350–$400 per month at Australian pharmacies at the full 3mg daily dose. That makes it one of the more expensive options per kilogram lost: newer weekly medications cost a similar amount or less and produce greater average weight loss in trials.
Is Saxenda as effective as Wegovy or Mounjaro?
On trial data, no. Average body-weight loss over roughly a year of treatment:
Ready to speak with an Australian GP about weight loss?
Request a bulk billed telehealth weight loss consultation. No referral required.
| Medication | Dosing | Average weight loss (trials) | Indicative monthly cost |
|---|---|---|---|
| Saxenda (liraglutide) | Daily injection | ~5–8% | $350–$400 |
| Wegovy (semaglutide 2.4mg) | Weekly injection | ~15% | $260–$320 |
| Mounjaro (tirzepatide) | Weekly injection | ~15–20% | $230–$460 by dose |
That's why most Australian GPs now consider semaglutide or tirzepatide first-line when a GLP-1 is appropriate — better results, fewer injections, comparable or lower cost. Our complete medication comparison covers the whole field.
Who might still choose Saxenda?
- Patients who tolerated it well previously and want to restart something familiar.
- Patients who can't tolerate semaglutide or tirzepatide — individual side-effect responses genuinely differ between GLP-1s.
- Patients whose GP prefers shorter-acting therapy — a daily drug clears the system faster if side effects appear, which occasionally matters clinically.
Is Saxenda being phased out in Australia?
Novo Nordisk has shifted its weight management focus decisively to semaglutide, and Saxenda's role keeps shrinking globally. It remains TGA-registered and available in 2026, but expect availability to narrow over time. If you're currently on Saxenda and wondering whether to switch to a weekly medication, that's a straightforward GP conversation — book a bulk billed telehealth consultation and bring your treatment history.
Getting assessed
Whether Saxenda, Wegovy, Mounjaro or no medication at all is right for you depends on your BMI, health history, previous attempts and budget. Our AHPRA-registered GPs assess all of this in a bulk billed telehealth consultation and prescribe only where clinically appropriate. Request an appointment — no referral needed, Australia-wide.
Prices indicative as at mid-2026; confirm with your pharmacy. All weight loss medications are prescription-only and subject to GP assessment of clinical suitability.
Ready to speak with an Australian GP about weight loss?
Request an appointment with Weight Loss GP Australia — bulk billed through Medicare. No referral required.
Book a Consultation